Compare JFU & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | JFU | GRML |
|---|---|---|
| Founded | 2006 | N/A |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.6M | 34.9M |
| IPO Year | 2018 | 2022 |
| Metric | JFU | GRML |
|---|---|---|
| Price | $2.63 | $0.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.5K | ★ 7.3M |
| Earning Date | 12-09-2022 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.53 | $0.16 |
| 52 Week High | $9.48 | $0.55 |
| Indicator | JFU | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 50.98 | 42.26 |
| Support Level | N/A | $0.16 |
| Resistance Level | $2.88 | $0.30 |
| Average True Range (ATR) | 0.13 | 0.03 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 60.00 | 15.20 |
9F Inc is a digital technology and wealth management service provider aiming to empower institutional partners with financial technologies as well as attract investors with investment opportunities that come with the vast potential of China's new consumer economy and the appreciation of world-wide assets and access to quality products at a competitive price. The Company's operations are organized into segments, consisting of E-commerce services, technology Empowerment service, and Wealth Management services.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.